✦ LIBER ✦

Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating

✍ Scribed by van den Heuvel, Michel M.; Uyterlinde, Wilma; Vincent, Andrew D.; de Jong, Jeroen; Aerts, Joachim; Koppe, Frederike; Knegjens, Joost; Codrington, Henk; Kunst, Peter W.E.; Dieleman, Edith; Verheij, Marcel; Belderbos, José

Book ID: 122156707
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 516 KB
Volume: 110
Category: Article
ISSN: 0167-8140
DOI: 10.1016/j.radonc.2013.10.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II, randomized, multicenter stud

A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer

✍ Christos Chouaid; Faith Nathan; Kristine Pemberton; Thomas Morris 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 244 KB

9121 POSTER A Multi-center, Open, Random

9121 POSTER A Multi-center, Open, Randomized, Phase II Study to Investigate the Sequential Administration of Docetaxel and Intermittent Erlotinib Versus Erlotinib as a Second-line Therapy for Advanced Non-small Cell Lung Cancer (NSCLC)

✍ Aparisi, F.; Sánchez, A.; Giner, V.; Mufioz, J.; Esquerdo, G.; Garde, J.; Garcia 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB